1/En Australia lo tienen claro respecto a Novavax:
‘Even within our country, we’re going to need a range of different vaccines that cater potentially for different populations or different comorbidities, for example, and different environments,’ he said.
‘While we see the mRNA vaccines are highly efficacious, they’re not as broadly applicable because of the extreme cold chain.
‘[NVX-CoV2373] is a vaccine that looks to be very well tolerated, but also very temperature stable. So for a country with conditions like ours, it may well be that the Novavax vaccine is actually the one that that we use the most in the end.
‘A lot less infrastructure is required to use this vaccine … so that’s going to mean, hopefully, they can be much easier to distribute through GP clinics.’
If all goes well, the vaccine could become available in Australia as early as April – although that will be dependent on the success of the ongoing trials, along with it being approved by the Therapeutic Goods Administration.
Associate Professor Griffin says he has great faith in this process, not just in terms of Novavax, but also the registering of Pfizer/BioNTech and AstraZeneca/Oxford University’s candidates.
2/ siguen aumentando fallecidos (29) y PFIZER/MODERNA están en duda:
Norway has stopped vaccinating those over 75. They are now up to 29 deaths after the 1st dose of the Pfizer vaccine in the 75+ age group (per The Norwegian Medicines Agency). Norway does not use the Moderna vaccine as such there is not clarity if this increase in projected death risk us related to Pfizers vaccine specifically or if it is mRNA vaccine related broadly.
SII CEO notes Novavax in India to scale up in May/June. Targeted for export to 'high income' countries at ~2x AZN/Oxford cost (so $6-$8?). Doesn't see $NVAX for India except if needed, and then in 2022. Hard to see 1B doses in 2021 by SII.
Además, sobre precios de COVAX y SII:
COVAX seems to pay 10.76$ (=1.6/0.15) per dose.
"In exchange for this firm commitment these participants will be required to provide a lower upfront payment of US$ 1.60 per dose, or 15% of the total cost per dose."
1) 50% Royalty of SII revenue = 10.67$/2 = 5,34$ plus
2) cost of MatrixM (as SII now produces the antigen per amendment of the contract)
Es por esto entre otras cosas (como comenté hace unos días) que yo no veo a las mRNA para la gripe o para los siguientes años del COVID (a no ser que avance la tecnología).
Siempre que haya alternativas más baratas y seguras claro, que a pesar de que todo apunta a que será así, se tiene que confirmar...
Under an agreement with the US drug developer, the Pune based drugmaker will develop two hundred crore doses of Novavax's vaccine candidate annually.
Si esto es así, se aprueba, es efectiva y segura y se necesita un chute anual son 10B al año. Mucho condicionante, pero con buenas probabilidades todos ellos...
“Lexington doctor on COVID-19 vaccines”
The other vaccine is by Novavax. “This technology that Novavax is working on is thought to be likely the future of vaccines,” Dr. Stanton says.
Acabo de localizar una joya de vídeo del CEO del Serum institut of India hablando sobre novavax y dice lo siguiente:
- Precio de la vacuna será del doble de Astra Zeneca
- Estará disponible en los próximos seis meses en el mercado indio
- Resultados ultima semana enero/primera febrero ( U.K. y SA)
- antígeno muy potente y respuesta inmune a largo plazo